BioVaxys Technology Corp.
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.
BioVaxys Technology Corp. (BIOV)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Bulletins
2023-1131 - Reinstatement - BioVaxys Technology Corp. (BIOV)
le 24 Novembre/November2023
Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.
The Company has rectified the situation that gave rise to the suspension.
____________________________
À compter d'aujourd'hui, BioVaxys Technology Corp. sera réintégré à la négociation.
La Société a rectifié la situation qui a donné lieu à la suspension.